AI	strong recommendation, high-quality evidence (IDSA); strong evidence and evidence from ≥1 RCT (ECIL-6); strong recommendation and evidence from ≥1 RCT (ESCMID)
AII	strong recommendation, moderate-quality evidence (IDSA); strong evidence and evidence from ≥1 non-randomized clinical trial, cohort, or case-controlled study (ECIL-6); strong recommendation and evidence from ≥1 non-randomized clinical trial, cohort, or case-controlled study (ESCMID)
AIII	strong recommendation, low-quality evidence (IDSA); strong evidence and opinion from respected authorities (ECIL-6); strong recommendation and opinion of respected authorities (ESCMID)
BI	strong or moderate evidence and evidence from ≥1 RCT (ECIL-6); moderate support and evidence from ≥1 RCT (ESCMID)
BII	strong or moderate evidence and evidence from ≥1 non-randomized clinical trial, cohort, or case-controlled study (ECIL-6); moderate support and evidence from ≥1 non-randomized clinical trial, cohort, or case-controlled study (ESCMID)
CI	weak recommendation, high-quality evidence (IDSA); insufficient evidence for efficacy and evidence from ≥1 RCT (ECIL-6); marginal support and evidence from ≥1 RCT (ESCMID)
CII	weak recommendation, moderate-quality evidence (IDSA); insufficient evidence for efficacy and evidence from ≥1 non-randomized clinical trial, cohort, or case-controlled study (ECIL-6); marginal support and evidence from ≥1 non-randomized clinical trial, cohort, or case-controlled study (ESCMID)
CIII	weak evidence, low-quality evidence (IDSA); insufficient evidence for efficacy and opinion from respected authorities (ECIL-6); marginal support and evidence of respected authorities (ESCMID)
DIII	moderate evidence against efficacy and opinion from respected authorities (ECIL-6); recommendation against use and evidence of respected authorities (ESCMID)